moving towards a daratumumab standard of care in mm
Published 5 years ago • 117 plays • Length 1:19Download video MP4
Download video MP3
Similar videos
-
3:57
daratumumab in the treatment of mm with high-risk cytogenetics
-
2:03
mechanism of action of daratumumab
-
5:07
daratumumab in the management of al amyloidosis
-
1:53
exploring daratumumab as a treatment option for patients with t-all
-
1:09
daratumumab enhancement for mm: the clinical impact
-
1:28
campus all updates: the safety and efficacy of daratumumab for the treatment of all
-
2:42
promising results for daratumumab in the front line setting
-
4:36
what is isatuximab? and how does it compare with daratumumab?
-
13:43
darzalex® iv (daratumumab) mechanism of action for multiple myeloma
-
4:01
choosing between isatuximab & daratumumab in multiple myeloma
-
1:14
insights into the management of mds/mpn overlap syndromes & advice for clinicians
-
1:04
revolutionizing mm treatment with daratumumab
-
1:03
columba study update: subcutaneous daratumumab in r/r mm
-
2:04
a novel mechanism of action for daratumumab in myeloma
-
2:41
optimizing the use of daratumumab in al amyloidosis
-
1:21
daratumumab with atra in r/r mm
-
3:07
daratumumab-based frontline therapy in al amyloidosis: real-world mayo clinic experience
-
2:30
daratumumab and isatuximab in the treatment of multiple myeloma
-
2:17
moving towards fixed-duration treatment in multiple myeloma
-
1:48
a phase ii study of daratumumab and pomalidomide in previously treated patients with al amyloidosis
-
2:39
subcutaneous daratumumab: an update on the latest mm clinical trials
-
1:05
daratumumab: no evidence of disease after treatment?